Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.44
- Piotroski Score 7.00
- Grade Neutral
- Symbol (SYNH)
- Company Syneos Health, Inc.
- Price $42.98
- Changes Percentage (0.02%)
- Change $0.01
- Day Low $42.97
- Day High $42.99
- Year High $52.23
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/02/2023
- Fiscal Year End N/A
- Average Stock Price Target $77.50
- High Stock Price Target $105.00
- Low Stock Price Target $25.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.70
- Trailing P/E Ratio 61.4
- Forward P/E Ratio 61.4
- P/E Growth 61.4
- Net Income $266.50 M
